Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConvaTec Regulatory News (CTEC)

Share Price Information for ConvaTec (CTEC)

Share Price is delayed by 15 minutes
Get Live Data
211.60    -0.20 (-0.09%)
Bid:
212.20
Ask:
212.60
Spread: 0.40 (0.189%)
Market Cap: £4.14b
CTEC Live PriceLast checked at - London Stock Exchange

Intraday ConvaTec Share Chart

Director/PDMR Shareholding

8 Sep 2025 16:50

RNS Number : 4654Y
Convatec Group PLC
08 September 2025
 

8 September 2025

Convatec Group Plc

("Convatec" or "the Company")

 

Director/PDMR Shareholding

 

 

This announcement provides information on Persons Discharging Managerial Responsibility ("PDMR") dealings under the Convatec 2017 Save as You Earn share option scheme (the "SAYE Scheme") that took place from 2022 to present.

 

Grant of SAYE options

 

On 14 July 2022, options were granted to Jonny Mason, Interim Chief Executive Officer (then Chief Financial Officer) and PDMR over 10,346 ordinary shares of 10 pence each in the Company ("Shares") at an option price of 173.97 pence per Share under the SAYE Scheme. The options became exercisable in the ordinary course from 1 September 2025.

 

On 20 July 2023, options were granted to Karim Bitar, Chief Executive Officer and PDMR over 10,253 Shares at an option price of 175.55 pence per Share under the SAYE Scheme. The options will become exercisable in the ordinary course from 1 September 2026.

 

Exercise of SAYE options

 

On 5 September 2025, Jonny Mason, exercised options over 10,346 Shares granted on 14 July 2022 under the SAYE Scheme, at an option price of 173.97 pence per Share.

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 

Details of the person discharging managerial responsibilities / person closely associated

 

Name

 

Jonny Mason

 

Reason for the notification

 

 

Position/status

 

Interim Chief Executive Officer and PDMR

 

Initial notification /Amendment

 

Initial notification

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

Name

 

Convatec Group Plc

 

LEI

 

213800LS272L4FIDOH92

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

Description of the financial instrument, type of instrument

Ordinary shares of 10p each in Convatec Group Plc

 

 

Identification code

GB00BD3VFW73

 

 

Nature of the transaction

Grant of options granted under the Convatec Group Plc 2017 Save As You Earn scheme

 

Price(s) and volume(s)

 

 

 

 

Price(s)

Volume(s)

£ 1.7397

10,346

 

Aggregated information

 

 

- Aggregated volume

N/A

 

 

- Price

 

 

Date of the transaction

 

14 July 2022

 

Place of the transaction

 

Outside a trading venue

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

Description of the financial instrument, type of instrument

Ordinary shares of 10p each in Convatec Group Plc

Identification code

GB00BD3VFW73

Nature of the transaction

Exercise of options granted under the Convatec Group Plc 2017 Save As You Earn scheme

Price(s) and volume(s)

 

 

 

 

Price(s)

Volume(s)

£ 1.7397

10,346

Aggregated information

- Aggregated volume

N/A - single transaction

- Price

Date of the transaction

 

5 September 2025

Place of the transaction

 

Outside a trading venue

 

 

 

Details of the person discharging managerial responsibilities / person closely associated

Name

 

Karim Bitar

Reason for the notification

 

Position/status

 

Chief Executive Officer and PDMR

Initial notification /Amendment

 

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

 

Convatec Group Plc

LEI

 

213800LS272L4FIDOH92

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

Description of the financial instrument, type of instrument

Ordinary shares of 10p each in Convatec Group Plc

Identification code

GB00BD3VFW73

Nature of the transaction

Grant of options granted under the Convatec Group Plc 2017 Save As You Earn scheme

Price(s) and volume(s)

 

 

 

 

Price(s)

Volume(s)

£ 1.7555

10,253

Aggregated information

- Aggregated volume

N/A

- Price

Date of the transaction

 

20 July 2023

Place of the transaction

 

Outside a trading venue

 

 

 

Contacts

The person responsible for making this announcement is James Kerton, Company Secretary, Convatec Group plc: cosec@convatec.com

 

Media: MediaRelations@convatec.com

 

Investor Relations: IR@convatec.com

 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

 

Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFVEAVITIIE
Date   Source Headline
13th Sep 202212:09 pmEQSConvatec Group PLC: Scrip Dividend – Calculation Price
13th Sep 202212:08 pmEQSConvatec Group PLC: Scrip Dividend – Calculation Price
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
4th Aug 20227:00 amRNSInterim Results
7th Jul 202211:53 amRNSDirector Declaration
28th Jun 20225:26 pmRNSBlock listing Interim Review
31st May 20222:00 pmRNSTotal Voting Rights
19th May 202210:00 amRNSDirector/PDMR Shareholding
12th May 20224:25 pmRNSResult of AGM
12th May 20227:00 amRNSAGM Trading Update
4th May 20223:31 pmRNSScrip Dividend - Total Issued Shares
3rd May 20227:00 amRNSNotice of Forthcoming Scheduled IR Events
7th Apr 20223:45 pmRNSScrip Dividend – Calculation Price
1st Apr 20224:00 pmRNSHolding(s) in Company
31st Mar 20223:45 pmRNSTotal Voting Rights
30th Mar 202212:00 pmRNSAnnual Report and Accounts 2021 and Notice of AGM
25th Mar 20222:00 pmRNSDirector/PDMR Shareholding
23rd Mar 202211:30 amRNSDirector/PDMR Shareholding
17th Mar 20222:40 pmRNSDirector/PDMR Shareholding
17th Mar 20222:20 pmRNSBoard Change
14th Mar 20227:00 amRNSAcquisition Completion of Triad Life Sciences Inc
8th Mar 20227:00 amRNSAnnual Results
28th Feb 202211:00 amRNSNon-Executive Director Changes
10th Feb 20223:15 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSAcquisition: entry into attractive wound biologics
27th Jan 202211:00 amRNSBoard Committee Changes
20th Dec 20218:45 amRNSBlock Listing Application
16th Dec 20212:00 pmRNSNon-Executive Director appointment
9th Dec 20217:00 amRNSChief Financial Officer succession
1st Nov 20213:35 pmRNSTotal Voting Rights
29th Oct 20217:00 amRNSQ3 Trading Update
18th Oct 20214:30 pmRNSDirector/PDMR Shareholding
1st Oct 20217:00 amRNSPricing of $500M 3.875% Senior Notes due 2029
30th Sep 20211:13 pmRNSConvaTec Announces Offer of $500M Senior Notes
28th Sep 20213:15 pmRNSScrip Dividend - Total Issued Shares
9th Sep 20213:00 pmRNSScrip Dividend - Calculation Price
30th Jul 20213:45 pmRNSDirector/PDMR Shareholding
30th Jul 20217:00 amRNSInterim Results
28th Jun 202112:40 pmRNSDirector Declaration
1st Jun 202111:45 amRNSTotal Voting Rights
17th May 20213:15 pmRNSDirector/PDMR Shareholding
7th May 20212:50 pmRNSResult of AGM
29th Apr 20217:00 amRNSQ1 Trading Update
28th Apr 202112:45 pmRNSScrip Dividend - Total Issued Shares
12th Apr 20213:15 pmRNSScrip Dividend - Calculation Price
22nd Mar 20213:40 pmRNSAnnual Report and Accounts 2020 and Notice of AGM
11th Mar 20213:50 pmRNSDirector/PDMR Shareholding
5th Mar 20217:00 amRNSAnnual Results
22nd Feb 202111:30 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.